MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
1.450
+0.020
+1.40%
After Hours: 1.470 +0.02 +1.38% 19:23 04/08 EDT
OPEN
1.500
PREV CLOSE
1.430
HIGH
1.500
LOW
1.420
VOLUME
45.13K
TURNOVER
--
52 WEEK HIGH
5.82
52 WEEK LOW
1.170
MARKET CAP
14.28M
P/E (TTM)
-0.3263
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INAB last week (0330-0403)?
Weekly Report · 2d ago
IN8bio grants 11,800 inducement stock options to new hires under Nasdaq rule
Reuters · 5d ago
IN8BIO REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Weekly Report: what happened at INAB last week (0323-0327)?
Weekly Report · 03/30 10:41
IN8bio announces 2026 annual stockholders meeting; FY2025 audit fees rise to $399,889
Reuters · 03/26 20:09
Weekly Report: what happened at INAB last week (0316-0320)?
Weekly Report · 03/23 10:36
IN8BIO Inc. publishes corporate presentation on gamma-delta T cell therapies in oncology and autoimmune diseases
Reuters · 03/17 14:10
Weekly Report: what happened at INAB last week (0309-0313)?
Weekly Report · 03/16 10:35
More
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.

Webull offers IN8bio Inc stock information, including NASDAQ: INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.